



## Claims

1. Microparticles comprising a somatostatin analogue comprising the amino acid sequence of formula I





1

wherein  $X_1$  is a radical of formula (a) or (b)



wherein R<sub>1</sub> is optionally substituted phenyl,


$R_2$  is  $-Z_1-CH_2-R_1$ ,  $-CH_2-CO-O-CH_2-R_1$ ,



X<sub>2</sub> is an α-amino acid having an aromatic residue on the C<sub>α</sub> side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His, (Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys<sup>9</sup> of the native somatostatin-14

in free form, salt form, or protected form,  
embedded in a polymer matrix.

2. Microparticles according to claim 1 wherein the somatostatin analogue is a compound of formula III



wherein the configuration at C-2 is (R) or (S) or a mixture thereof, and

- 22 -

wherein R is  $\text{NR}_1\text{R}_2\text{-C}_{2-6}\text{alkylene}$  or  $\text{guanidine-C}_{2-6}\text{alkylene}$ , and each of  $\text{R}_1$  and  $\text{R}_2$  independently is H or  $\text{C}_{1-4}\text{alkyl}$ ,  
in free form, salt form or protected form.

3. Microparticles according to claim 1 or 2 wherein the somatostatin analogue is in pamoate salt form.
4. Microparticles according to any preceding claim wherein the polymer matrix comprises a linear or branched polylactide-co-glycolide.
5. Microparticles according to any preceding claim wherein the polymeric matrix comprises at least two different polymers.
6. Microparticles according to any preceding claim further comprising a surfactant, a porosity influencing agent and/or a basic salt.
7. A pharmaceutical composition comprising microparticles of any preceding claim and a water-based vehicle comprising a wetting agent.
8. A composition according to claim 7 wherein the wetting agent comprises a poloxamer and/or a polyoxyethylene-sorbitan-fatty acid ester.
9. A composition according to any one of claims 7 or 8 wherein the vehicle comprises a tonicity agent.
10. A composition according to any one of claims 7 or 8 wherein the vehicle comprises a viscosity increasing agent.
11. A kit comprising microparticles according to any one of claims 1 to 6 and a water-based vehicle.
12. Use of microparticles according to any one of claims 1 to 6 or of a pharmaceutical composition according to any one of claims 7 to 10 for the preparation of a medicament for the treatment of a disease or disorder with an aetiology comprising or associated with excess GH- and/or IGF-1 secretion.
13. A method of treating a disease or disorder with an aetiology comprising or associated with excess GH- and/or IGF-1 secretion in a subject in need thereof which comprises administering microparticles according to any one of claims 1 to 6 or of a pharmaceutical composition according to any one of claims 7 to 10 to the subject.